The global immuno-oncology assays market is projected to reach USD 7.9 billion by 2026 from USD 4.4billion in 2021, at a CAGR of 12.5% during the forecast period. Market growth is driven by factors such as the growing significance of companion diagnostics in drug development and rising incidence of cancer and growing adoption of targeted therapies. On the other hand,the requirement of high capital investments and low cost-benefit ratio and the unfavorable regulatory and reimbursement scenario are the major factors hampering the growth of this market.
The consumables segment accounted for the highest growth rate in theimmuno-oncology assaysmarket, by product& service, during the forecast period The immuno-oncology assays market is segmented into consumables, instruments, and software & services based on product & service.In 2020, the consumables segment accounted for the highest growth rate in the immuno-oncology assays market.
The requirement of consumables in large numbers as compared to instruments is the major factor contributing to the growth of this segment.
Research applications segment accounted for the highest CAGR Based on application, the immuno-oncology assays market is segmented into research applications and clinical diagnostics.In 2020, the research applications segmentaccounted for the highest growth rate.
This can be attributed to the rising prominence of biomarker-based drug development.
Asia Pacific: The fastest-growing regionimmuno-oncology assays market The global immuno-oncology assays market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.The Asia Pacific region is projected to register the highest CAGR during the forecast period.
Growth in this region is expected to be centeredon China and Japan. Factors such as the growing number of CROs in the region and the increasing awareness about the early detection of cancer are driving the growth of the immuno-oncology assays market in this region.
The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1 - 40%, Tier 2 - 30%,and Tier 3 -30% • By Designation: C-level - 27%, D-level - 18%, and Others - 55% • By Region: North America -51%, Europe - 21%, Asia Pacific - 18%, Latin America – 6%, and the Middle East & Africa – 4%
Lists of Companies Profiled in the Report: • Thermo Fisher Scientific, Inc. (US) • F. Hoffmann-La Roche Ltd. (Switzerland) • Agilent Technologies, Inc. (US) • Illumina, Inc. (US) • NanoString Technologies, Inc. (US) • Sartorius AG (Germany) • HTG Molecular Diagnostics, Inc. (US) • QIAGEN N.V. (Netherlands) • Merck Millipore (US) • PerkinElmer, Inc. (US) • Abbott Laboratories, Inc. (US) • Guardant Health, Inc. (US) • bioMérieux SA (France) • Myriad Genetics, Inc. (US) • MESO SCALE DIAGNOSTICS, LLC. (US) • Seegene Inc. (South Korea) • Bio-Rad Laboratories, Inc. (US) • Charles River Laboratories, Inc. (US) • Olink (Sweden) • ASURAGEN, INC. (US) • Invivoscribe, Inc. (US) • Creative Biolabs (US) • ReachBio LLC (US) • NMI Technologietransfer GmbH (Germany)
Research Coverage: This report provides a detailed picture of the global immuno-oncology assays market.It aims at estimating the size and future growth potential of the market across different segments, such as product& service, technology, indication, application, and region.
The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall immuno-oncology assays market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
Our reports have been used by over 10K customers, including:
279 pages •
By The Business Research Company
• Jul 2022
Interventional Oncology Devices Global Market Opportunities And Strategies To 2031 provides the strategists; marketers and senior management with the critical information they need to assess the global interventional oncology devices market as it emerges from the COVID-19 shut down. Description: Where is the largest...
304 pages •
By The Business Research Company
• Jul 2022
Immuno-Oncology Drugs Global Market Opportunities And Strategies To 2031 provides the strategists; marketers and senior management with the critical information they need to assess the global immuno-oncology drugs market as it emerges from the COVID 19 shut down. Description: Where is the largest and fastest growing...
288 pages •
By The Business Research Company
• Jul 2022
Community Oncology Services Global Market Opportunities And Strategies To 2031: COVID-19 Growth And Change provides the strategists; marketers and senior management with the critical information they need to assess the global community oncology services market as it emerges from the COVID 19 shut down. Description: Where...
Oncology information systems manage data from various treatment schedules, treatment plans, and treatment delivery for each patient.Focus on laying a framework on standardization in OIS is further advancing the level of care for each cancer patient through a multidisciplinary approach. Factors such as increasing adoption of OIS solutions...
263 pages •
By Asia Market Information & Development Company
• May 2022
China’s demand for Cancer Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer...
The global interventional oncology market size is projected to reach USD 2.9 billion by 2026 from USD 1.9 billion in 2020, at a CAGR of 6.8%. Factors such as the technological advancements in the market are propelling the growth of the interventional oncology market. Additionally, rising cases of surgeries, investments from both private and...
442 pages •
By The Business Research Company
• Nov 2020
Oncology Drugs Global Market Opportunities And Strategies To 2030: COVID-19 Impact and Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global oncology drugs market. Description: Where is the largest and fastest growing market for the oncology...
The global cold plasma equipment market is expected to reach US$ 308.87 Mn in 2027 from US$ 96.67 Mn in 2019. The market is estimated to grow with a CAGR of 15.6% from 2020-2027. The growth of the cold plasma equipment market is primarily attributed to the factors such as increasing use of cold plasma in medical treatment, increasing...
The cold plasma equipment market in Asia Pacific is anticipated to reach US$ 50.04 million by 2027 from US$ 14.20 million in 2019; it is projected to grow at a CAGR of 17.1% from 2020 to 2027. The growth of the cold plasma equipment market in Asia Pacific is primarily ascribed to the increasing use of cold plasma in therapeutics, growing...
The global cold plasma equipment market is expected to reach US$ 308.14 Mn in 2027 from US$ 96.67 Mn in 2019. The market is estimated to grow with a CAGR of 15.7% from 2020-2027. The growth of the cold plasma equipment market is primarily attributed to the factors such as increasing use of cold plasma in medical treatment, increasing hospital...
Wound Care
Cancer
Oncology
APAC
World
Europe
Middle East
Africa
Central America
Health Expenditure
Cancer Incidence
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.